Всемирная психиатрия. №1 2020

Дофамин и глутамат при шизофрении

Robert A. McCutcheon1,2,3, John H. Krystal4,5,6, Oliver D. Howes1,2,3

1Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK 2MRC London Institute of Medical Sciences, Imperial College London, Hammersmith Hospital, London, UK 3South London and Maudsley Foundation NHS Trust, Maudsley Hospital, London, UK 4Department of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, CT, USA 5Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA 6VA National Center for PTSD, VA Connecticut Healthcare System, West Haven, CT, USA

Стр. 15-32

4715 просмотров

Опубликовано: 12 февраля 2020

Аннотация / Abstract

a:2:{s:4:"TEXT";s:65533:"a:2:{s:4:"TYPE";s:4:"HTML";s:4:"TEXT";s:114738:"Перевод: Скугаревская Т.О. (Минск) Редактура: к.м.н. Федотов И.А. (Рязань) McCutcheon RA, Krystal JH, Howes OD Dopamine and glutamate in schizophrenia: biology, symptoms and treatment. World Psychiatry 2020;19(1):15-33. Резюме Дофаминергическая и глутаматергическая системы играют различные роли в нейронном сигнализировании, однако обе системы считаются в значительной мере вовлеченными в патофизиологию шизофрении. В данной статье мы рассматриваем исследования, которые изучали вклад обеих систем в этиологию расстройства. Мы проанализируем свидетельства посмертных, доклинических фармакологических и in vivo нейровизуализационных исследований. Фармакологические и доклинические исследования задействуют обе системы, в то время как прижизненная визуализация дофаминергической системы стабильно свидетельствует о повышенном уровне синтеза и выделения дофамина в стриатуме при шизофрении. Визуализация глутаматергической системы и другие исследования дофаминергической системы произвели менее последовательные выводы, что может быть связано с методологическими ограничениями и гетерогенностью расстройства. Сходящиеся доказательства свидетельствуют о том, что генетические и средовые факторы риска шизофрении определяют нарушения глутаматного и дофаминового функционирования. Одна...

Перевод: Скугаревская Т.О. (Минск) Редактура: к.м.н. Федотов И.А. (Рязань) McCutcheon RA, Krystal JH, Howes OD Dopamine and glutamate in schizophrenia: biology, symptoms and treatment. World Psychiatry 2020;19(1):15-33. Резюме Дофаминергическая и глутаматергическая системы играют различные роли в нейронном сигнализировании, однако обе системы считаются в значительной мере вовлеченными в патофизиологию шизофрении. В данной статье мы рассматриваем исследования, которые изучали вклад обеих систем в этиологию расстройства. Мы проа...

Материал для специалистов

Полный текст статьи доступен только зарегистрированным пользователям.

Вход / Регистрация

1. McCutcheon RA, Marques TR, Howes OD. Schizophrenia: an overview. JAMA Psychiatry (in press).
2. Hjorthøj C, Stürup AE, McGrath JJ et al. Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis. Lancet Psychiatry 2017; 4: 295-301.
3. van Rossum JM. The significance of dopamine-receptor blockade for the mechanism of action of neuroleptic drugs. Arch Int Pharmacodyn Thérapie 1966; 160: 492-4.
4. Kaar SJ, Natesan S, McCutcheon R et al. Antipsychotics: mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology. Neuropharmacology (in press).
5. Carlsson A, Lindqvist M, Magnusson T. 3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature 1957; 180: 1200.
6. Featherstone RE, Kapur S, Fletcher PJ. The amphetamine-induced sensitized state as a model of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 1556-71.
7. Kellendonk C, Simpson EH, Polan HJ et al. Transient and selective overexpression of dopamine D2 receptors in the striatum causes persistent abnormalities in prefrontal cortex functioning. Neuron 2006; 49: 603-15.
8. Petty A, Cui X, Tesiram Y et al. Enhanced dopamine in prodromal schizophrenia (EDiPS): a new animal model of relevance to schizophrenia. NPJ Schizophr 2019; 5: 6.
9. Grace AA. Dopamine system dysregulation and the pathophysiology of schizophrenia: insights from the methylazoxymethanol acetate model. Biol Psychiatry 2017; 81: 5-8.
10. Lapiz MDS, Fulford A, Muchimapura S et al. Influence of postweaning social isolation in the rat on brain development, conditioned behavior, and neurotransmission. Neurosci Behav Physiol 2003; 33: 13-29.CAS
11. Bowers MB. Central dopamine turnover in schizophrenic syndromes. Arch Gen Psychiatry 1974; 31: 50-4.
12. Kahn RS, Harvey PD, Davidson M et al. Neuropsychological correlates of central monoamine function in chronic schizophrenia: relationship between CSF metabolites and cognitive function. Schizophr Res 1994; 11: 217-24.
13. Gattaz WF, Riederer P, Reynolds GP et al. Dopamine and noradrenalin in the cerebrospinal fluid of schizophrenic patients. Psychiatry Res 1983; 8: 243-50.
14. Gattaz WF, Gasser T, Beckmann H. Multidimensional analysis of the concentrations of 17 substances in the CSF of schizophrenics and controls. Biol Psychiatry 1985; 20: 360-6.
15. Frecska E, Perényi A, Bagdy G et al. CSF dopamine turnover and positive schizophrenic symptoms after withdrawal of long-term neuroleptic treatment. Psychiatry Res 1985; 16: 221-6.
16. Bagdy G, Perényi A, Frecska E et al. Decrease in dopamine, its metabolites and noradrenaline in cerebrospinal fluid of schizophrenic patients after withdrawal of long-term neuroleptic treatment. Psychopharmacology 1985; 85: 62-4.
17. Maas JW, Bowden CL, Miller AL et al. Schizophrenia, psychosis, and cerebral spinal fluid homovanillic acid concentrations. Schizophr Bull 1997; 23: 147-54.
18. van Kammen DP, Kelley M. Dopamine and norepinephrine activity in schizophrenia. Schizophr Res 1991; 4: 173-91.
19. Post RM, Fink E, Carpenter WT et al. Cerebrospinal fluid amine metabolites in acute schizophrenia. Arch Gen Psychiatry 1975; 32: 1063-9.
20. Nybäck H, Berggren BM, Hindmarsh T et al. Cerebroventricular size and cerebrospinal fluid monoamine metabolites in schizophrenic patients and healthy volunteers. Psychiatry Res 1983; 9: 301-8.
21. Robinson DG, Woerner MG, Alvir JM et al. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry 1999; 156: 544-9. CASWeb of Science
22. Lee T, Seeman P. Elevation of brain neuroleptic/dopamine receptors in schizophrenia. Am J Psychiatry 1980; 137: 191-7.
23. Zakzanis KK, Hansen KT. Dopamine D2 densities and the schizophrenic brain. Schizophr Res 1998; 32: 201-6.
24. Silvestri S, Seeman MV, Negrete J-C et al. Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study. Psychopharmacology 2000; 152: 174-80.
25. Samaha A-N, Seeman P, Stewart J et al. “Breakthrough” dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time. J Neurosci 2007; 27: 2979-86.
26. Mueller HT, Haroutunian V, Davis KL et al. Expression of the ionotropic glutamate receptor subunits and NMDA receptor-associated intracellular proteins in the substantia nigra in schizophrenia. Mol Brain Res 2004; 121: 60-9.
27. Ichinose H, Ohye T, Fujita K et al. Quantification of mRNA of tyrosine hydroxylase and aromatic L-amino acid decarboxylase in the substantia nigra in Parkinson's disease and schizophrenia. J Neural Transm -Park Dis Dement Sect 1994; 8: 149-58.
28. Purves-Tyson TD, Owens SJ, Rothmond DA et al. Putative presynaptic dopamine dysregulation in schizophrenia is supported by molecular evidence from post-mortem human midbrain. Transl Psychiatry 2017; 7:e1003.
29. Williams MR, Galvin K, O'Sullivan B et al. Neuropathological changes in the substantia nigra in schizophrenia but not depression. Eur Arch Psychiatry Clin Neurosci 2014; 264: 285-96.
30. Gandal MJ, Zhang P, Hadjimichael E et al. Transcriptome-wide isoform-level dysregulation in ASD, schizophrenia, and bipolar disorder. Science 2018; 362: 6420. Web of Science
31 Seeman P, Lee T. Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science 1975; 188: 1217-9.
32. Creese I, Burt D, Snyder S. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 1976; 192: 481-3.
33. Huhn M, Nikolakopoulou A, Schneider-Thoma J et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet 2019; 394: 939-51.
34. Connell P. Amphetamine psychosis. BMJ 1957; 5018: 582.
35. Bell DS. The experimental reproduction of amphetamine psychosis. Arch Gen Psychiatry 1973; 29: 35-40.
36. Moskovitz C, Moses H, Klawans HL. Levodopa-induced psychosis: a kindling phenomenon. Am J Psychiatry 1978; 135: 669-75.
37. Voce A, Calabria B, Burns R et al. A systematic review of the symptom profile and course of methamphetamine-associated psychosis: substance use and misuse. Subst Use Misuse 2019; 54: 549-59.
38. Goff DC, Coyle JT. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry 2001; 158: 1367-77.
39. Balu DT, Li Y, Puhl MD et al. Multiple risk pathways for schizophrenia converge in serine racemase knockout mice, a mouse model of NMDA receptor hypofunction. Proc Natl Acad Sci USA 2013; 110: E2400-9.
40. Labrie V, Duffy S, Wang W et al. Genetic inactivation of D-amino acid oxidase enhances extinction and reversal learning in mice. Learn Mem 2009; 16: 28-37.
41. Carlson GC, Talbot K, Halene TB et al. Dysbindin-1 mutant mice implicate reduced fast-phasic inhibition as a final common disease mechanism in schizophrenia. Proc Natl Acad Sci USA 2011; 108: E962-70.
42. Kim JS, Kornhuber HH, Schmid-Burgk W et al. Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci Lett 1980; 20: 379-82.
43. Goff DC, Wine L. Glutamate in schizophrenia: clinical and research implications. Schizophr Res 1997; 27: 157-68.
44. Plitman E, Iwata Y, Caravaggio F et al. Kynurenic acid in schizophrenia: a systematic review and meta-analysis. Schizophr Bull 2017; 43: 764-77.
45 Hu W, Macdonald ML, Elswick DE et al. The glutamate hypothesis of schizophrenia: evidence from human brain tissue studies. Ann NY Acad Sci 2015; 1338: 38-57.
46. Javitt D, Zukin S. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991; 148: 1301-8.
47. Stone JM, Pepper F, Fam J et al. Glutamate, N-acetyl aspartate and psychotic symptoms in chronic ketamine users. Psychopharmacology 2014; 231: 2107-16.
48. Fan N, Xu K, Ning Y et al. Profiling the psychotic, depressive and anxiety symptoms in chronic ketamine users. Psychiatry Res 2016; 237: 311-5.
49. Cassidy CM, Zucca FA, Girgis RR et al. Neuromelanin-sensitive MRI as a noninvasive proxy measure of dopamine function in the human brain. Proc Natl Acad Sci USA 2019; 116: 5108-17.
50. Urban NBL, Slifstein M, Meda S et al. Imaging human reward processing with positron emission tomography and functional magnetic resonance imaging. Psychopharmacology 2012; 221: 67-77.
51. Radua J, Schmidt A, Borgwardt SJ et al. Ventral striatal activation during reward processing in psychosis: a neurofunctional meta-analysis. JAMA Psychiatry 2016; 72: 1243-51. Web of Science
52. Howes OD, Kambeitz J, Stahl D et al. The nature of dopamine dysfunction in schizophrenia and what this means for treatment. Arch Gen Psychiatry 2012; 69: 776-86.
53. Abi-Dargham A, van de Giessen E, Slifstein M et al. Baseline and amphetamine-stimulated dopamine activity are related in drug-naïve schizophrenic subjects. Biol Psychiatry 2009; 65: 1091-3.
54. Kegeles LS, Abi-Dargham A, Frankle WG et al. Increased synaptic dopamine function in associative regions of the striatum in schizophrenia. Arch Gen Psychiatry 2010; 67: 231-9.
55. Kubota M, Nagashima T, Takano H et al. Affinity states of striatal dopamine D2 receptors in antipsychotic-free patients with schizophrenia. Int J Neuropsychopharmacol 2017; 20: 928-35.
56. Mizrahi R, Addington J, Rusjan PM et al. Increased stress-induced dopamine release in psychosis. Biol Psychiatry 2012; 71: 561-7.
57. Frankle WG, Paris J, Himes M et al. Amphetamine-induced striatal dopamine release measured with an agonist radiotracer in schizophrenia. Biol Psychiatry 2018; 83: 707-14.
58. Slifstein M, Abi-Dargham A. Is it pre-or postsynaptic? Imaging striatal dopamine excess in schizophrenia. Biol Psychiatry 2018; 83: 635-7.
59. Guo N, Guo W, Kralikova M et al. Impact of D2 receptor internalization on binding affinity of neuroimaging radiotracers. Neuropsychopharmacology 2010; 35: 806-17.
60. Sun W, Ginovart N, Ko F et al. In vivo evidence for dopamine-mediated internalization of D2-receptors after amphetamine: differential findings with [3H]raclopride versus [3H]spiperone. Mol Pharmacol 2003; 63: 456-62.
61. Brugger SP, Angelescu I, Abi-Dargham A et al. Heterogeneity of striatal dopamine function in schizophrenia: meta-analysis of variance. Biol Psychiatry (in press). Web of Science
6.2 Stenkrona P, Matheson GJ, Halldin C et al. D1-dopamine receptor availability in first-episode neuroleptic naive psychosis patients. Int J Neuropsychopharmacol 2019; 22: 415-25.
63. Kambeitz J, Abi-Dargham A, Kapur S et al. Alterations in cortical and extrastriatal subcortical dopamine function in schizophrenia: systematic review and meta-analysis of imaging studies. Br J Psychiatry 2014; 204: 420-9.
64. Abi-Dargham A, Mawlawi O, Lombardo I et al. Prefrontal dopamine D1 receptors and working memory in schizophrenia. J Neurosci 2002; 22: 3708-19.
65. Abi-Dargham A, Xu X, Thompson JL et al. Increased prefrontal cortical D2 receptors in drug naive patients with schizophrenia: a PET study with [11C]NNC112. J Psychopharmacol 2012; 26: 794-805.
66. Kosaka J, Takahashi H, Ito H et al. Decreased binding of [11C]NNC112 and [11C]SCH23390 in patients with chronic schizophrenia. Life Sci 2010; 86: 814-8.
67. Hirvonen J, Van Erp TGM, Huttunen J et al. Brain dopamine D1 receptors in twins discordant for schizophrenia. Am J Psychiatry 2006; 163: 1747-53.
68. Okubo Y, Suhara T, Suzuki K et al. Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature 1997; 385: 634-6.
69. Karlsson P, Farde L, Halldin C et al. PET study of D(1) dopamine receptor binding in neuroleptic-naive patients with schizophrenia. Am J Psychiatry 2002; 159: 761-7.
70. Poels EMP, Girgis RR, Thompson JL et al. In vivo binding of the dopamine-1 receptor PET tracers [11C]NNC112 and [11C]SCH23390: a comparison study in individuals with schizophrenia. Psychopharmacology 2013; 228: 167-74.
71. Guo N, Hwang DR, Lo ES et al. Dopamine depletion and in vivo binding of PET D1 receptor radioligands: implications for imaging studies in schizophrenia. Neuropsychopharmacology 2003; 28: 1703-11.
72. Ekelund J, Slifstein M, Narendran R et al. In vivo DA D(1) receptor selectivity of NNC 112 and SCH 23390. Mol Imaging Biol 2007; 9: 117-25.
73. Lidow MS, Elsworth JD, Goldman-Rakic PS. Down-regulation of the D1 and D5 dopamine receptors in the primate prefrontal cortex by chronic treatment with antipsychotic drugs. J Pharmacol Exp Ther 1997; 281: 597-603. CASWeb of Science
74. Artiges E, Leroy C, Dubol M et al. Striatal and extrastriatal dopamine transporter availability in schizophrenia and its clinical correlates: a voxel-based and high-resolution PET study. Schizophr Bull 2017; 43: 1134-42.
75. Arakawa R, Ichimiya T, Ito H et al. Increase in thalamic binding of [11C]PE2I in patients with schizophrenia: a positron emission tomography study of dopamine transporter. J Psychiatr Res 2009; 43: 1219-23.
76. Taylor SF, Koeppe RA, Tandon R et al. In vivo measurement of the vesicular monoamine transporter in schizophrenia. Neuropsychopharmacology 2000; 23: 667-75.
77. Zubieta JK, Taylor SF, Huguelet P et al. Vesicular monoamine transporter concentrations in bipolar disorder type I, schizophrenia, and healthy subjects. Biol Psychiatry 2001; 49: 110-6.
78. Zucker M, Valevski A, Weizman A et al. Increased platelet vesicular monoamine transporter density in adult schizophrenia patients. Eur Neuropsychopharmacol 2002; 12: 343-7.
79. Egerton A, Mehta MA, Montgomery AJ et al. The dopaminergic basis of human behaviors: a review of molecular imaging studies. Neurosci Biobehav Rev 2009; 33: 1109-32.
80. Dewey SL, Logan J, Wolf AP et al. Amphetamine induced decreases in (18F)-N-methylspiroperidol binding in the baboon brain using positron emission tomography (PET). Synapse 1991; 7: 324-7.
81. Kumakura Y, Cumming P. PET studies of cerebral levodopa metabolism: a review of clinical findings and modeling approaches. Neuroscientist 2009; 15: 635-50.
82. Sawilowsky SS. New effect size rules of thumb. J Mod Appl Stat Methods 2009; 8: 597-9.
83. McCutcheon R, Beck K, Jauhar S et al. Defining the locus of dopaminergic dysfunction in schizophrenia: a meta-analysis and test of the mesolimbic hypothesis. Schizophr Bull 2018; 44: 1301-11.
84. Demjaha A, Murray RM, McGuire PK et al. Dopamine synthesis capacity in patients with treatment-resistant schizophrenia. Am J Psychiatry 2012; 169: 1203-10.
85 Abi-Dargham A, Gil R, Krystal J et al. Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am J Psychiatry 1998; 155: 761-7.
86 Jauhar S, Nour MM, Veronese M et al. A test of the transdiagnostic dopamine hypothesis of psychosis using positron emission tomographic imaging in bipolar affective disorder and schizophrenia. JAMA Psychiatry 2017; 74: 1206-13.
87 Hietala J, Syvälahti E, Vilkman H et al. Depressive symptoms and presynaptic dopamine function in neuroleptic-naive schizophrenia. Schizophr Res 1999; 35: 41-50.
88 Avram M, Brandl F, Cabello J et al. Reduced striatal dopamine synthesis capacity in patients with schizophrenia during remission of positive symptoms. Brain 2019; 142: 1813-26.
89 Egerton A, Demjaha A, McGuire P et al. The test-retest reliability of 18F-DOPA PET in assessing striatal and extrastriatal presynaptic dopaminergic function. Neuroimage 2010; 50: 524-31.
90 Howes OD, Williams M, Ibrahim K et al. Midbrain dopamine function in schizophrenia and depression: a post-mortem and positron emission tomographic imaging study. Brain 2013; 136: 3242-51.
91 Kumakura Y, Cumming P, Vernaleken I et al. Elevated [18F]fluorodopamine turnover in brain of patients with schizophrenia: an [18F]fluorodopa/positron emission tomography study. J Neurosci 2007; 27: 8080-7.
92 Elkashef A, Doudet D, Bryant T. 6-(18)F-DOPA PET study in patients with schizophrenia. Psychiatry Res Neuroimaging 2000; 100: 1-11.
93 Hall H, Sedvall G, Magnusson O et al. Distribution of D1-and D2-dopamine receptors, and dopamine and its metabolites in the human brain. Neuropsychopharmacology 1994; 11: 245-56.
94 Hernaus D, Mehta MA. Prefrontal cortex dopamine release measured in vivo with positron emission tomography: implications for the stimulant paradigm. Neuroimage 2016; 142: 663-7.
95. Slifstein M, Van De Giessen E, Van Snellenberg J et al. Deficits in prefrontal cortical and extrastriatal dopamine release in schizophrenia a positron emission tomographic functional magnetic resonance imaging study. JAMA Psychiatry 2015; 72: 316-24.
96. Schifani C, Tseng H-H, Kenk M et al. Cortical stress regulation is disrupted in schizophrenia but not in clinical high risk for psychosis. Brain 2018; 141: 2213-24.
97. Rao N, Northoff G, Tagore A et al. Impaired prefrontal cortical dopamine release in schizophrenia during a cognitive task : a [11C]FLB 457 positron emission tomography study. Schizophr Bull 2019; 45: 670-9.
98. Hernaus D, Collip D, Kasanova Z et al. No evidence for attenuated stress-induced extrastriatal dopamine signaling in psychotic disorder. Transl Psychiatry 2015; 5:e547.
99. Tseng H-H, Watts JJ, Kiang M et al. Nigral stress-induced dopamine release in clinical high risk and antipsychotic-naïve schizophrenia. Schizophr Bull 2018; 44: 542-51.
100. Abi-Dargham A, Kegeles LS, Zea-Ponce Y et al. Striatal amphetamine-induced dopamine release in patients with schizotypal personality disorder studied with single photon emission computed tomography and [123I]iodobenzamide. Biol Psychiatry 2004; 55: 1001-06.
101. Howes OD, Montgomery AJ, Asselin M-C et al. Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Arch Gen Psychiatry 2009; 66: 13-20.
102. Egerton A, Chaddock CA, Winton-Brown TT et al. Presynaptic striatal dopamine dysfunction in people at ultra-high risk for psychosis: findings in a second cohort. Biol Psychiatry 2013; 74: 106-12.
103. Howes OD, Bonoldi I, McCutcheon RA et al. Glutamatergic and dopaminergic function and the relationship to outcome in people at clinical high risk of psychosis: a multi-modal PET-magnetic resonance brain imaging study. Neuropsychopharmacology (in press).
104. Howes O, Bose S, Turkheimer FE et al. Dopamine synthesis capacity before onset of psychosis: a prospective [18F]-DOPA PET imaging study. Am J Psychiatry 2011; 168: 1311-7.
105. Howes OD, Shotbolt P, Bloomfield M et al. Dopaminergic function in the psychosis spectrum: an [18F]-DOPA imaging study in healthy individuals with auditory hallucinations. Schizophr Bull 2013; 39: 807-14.
106. Shotbolt P, Stokes PR, Owens SF et al. Striatal dopamine synthesis capacity in twins discordant for schizophrenia. Psychol Med 2011; 41: 2331-8.
107. van Duin EDA, Kasanova Z, Hernaus D et al. Striatal dopamine release and impaired reinforcement learning in adults with 22q11.2 deletion syndrome. Eur Neuropsychopharmacol 2018; 28: 732-42.
108. Huttunen J, Heinimaa M, Svirskis T et al. Striatal dopamine synthesis in first-degree relatives of patients with schizophrenia. Biol Psychiatry 2008; 63: 114-7.
109. Reith J, Benkelfat C, Sherwin A et al. Elevated dopa decarboxylase activity in living brain of patients with psychosis. Proc Natl Acad Sci USA 1994; 91: 11651-4.
110. Vingerhoets C, Bloemen OJN, Boot E et al. Dopamine in high-risk populations: a comparison of subjects with 22q11.2 deletion syndrome and subjects at ultra high-risk for psychosis. Psychiatry Res Neuroimaging 2018; 272: 65-70.
111. Brunelin J, d'Amato T, van Os J et al. Increased left striatal dopamine transmission in unaffected siblings of schizophrenia patients in response to acute metabolic stress. Psychiatry Res 2010; 181: 130-5.
112. Lee KJ, Lee JS, Kim SJ et al. Loss of asymmetry in D2 receptors of putamen in unaffected family members at increased genetic risk for schizophrenia. Acta Psychiatr Scand 2008; 118: 200-8.
113. Hirvonen J, van Erp TGM, Huttunen J et al. Striatal dopamine D1 and D2 receptor balance in twins at increased genetic risk for schizophrenia. Psychiatry Res 2006; 146: 13-20.
114. Fouriezos G, Hansson P, Wise RA. Neuroleptic-induced attenuation of brain stimulation reward in rats. J Comp Physiol Psychol 1978; 92: 661-71.
115. Schultz W, Dayan P, Montague PR. A neural substrate of prediction and reward. Science 1997; 275: 1593-9.
116. Lerner TN, Shilyansky C, Davidson TJ et al. Intact-brain analyses reveal distinct information carried by SNc dopamine subcircuits. Cell 2015; 162: 635-47.
117. Menegas W, Babayan BM, Uchida N et al. Opposite initialization to novel cues in dopamine signaling in ventral and posterior striatum in mice. Elife 2017; 6:e21886.
118. Menegas W, Akiti K, Amo R et al. Dopamine neurons projecting to the posterior striatum reinforce avoidance of threatening stimuli. Nat Neurosci 2018; 21: 1421-30.
119. Groessl F, Munsch T, Meis S et al. Dorsal tegmental dopamine neurons gate associative learning of fear. Nat Neurosci 2018; 21: 952-62.
120. Matsumoto M, Hikosaka O. Two types of dopamine neuron distinctly convey positive and negative motivational signals. Nature 2009; 459: 837-41.
121. Miller R. Schizophrenic psychology, associative learning and the role of forebrain dopamine. Med Hypotheses 1976; 2: 203-11. CAS
122. Kapur S. Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. Am J Psychiatry 2003; 160: 13-23.
123. McCutcheon RA, Abi-Dargham A, Howes OD. Schizophrenia, dopamine and the striatum: from biology to symptoms. Trends Neurosci 2019; 42: 205-20.
124. Sterzer P, Adams RA, Fletcher P et al. The predictive coding account of psychosis. Biol Psychiatry 2018; 84: 634-43.
125. Corlett PR, Krystal JH, Taylor JR et al. Why do delusions persist? Front Hum Neurosci 2009; 3: 12.
126. Powers AR, Mathys C, Corlett PR. Pavlovian conditioning-induced hallucinations result from overweighting of perceptual priors. Science 2017; 357: 596-600.
127. Cassidy CM, Balsam PD, Weinstein JJ et al. A perceptual inference mechanism for hallucinations linked to striatal dopamine. Curr Biol 2018; 28: 503-14.
128. Nour MM, Dahoun T, Schwartenbeck P et al. Dopaminergic basis for signaling belief updates, but not surprise, and the link to paranoia. Proc Natl Acad Sci USA 2018; 115: E10167-76
129. McCutcheon RA, Bloomfield MAP, Dahoun T et al. Chronic psychosocial stressors are associated with alterations in salience processing and corticostriatal connectivity. Schizophr Res 2019; 213: 56-64.
130. Uddin LQ. Salience processing and insular cortical function and dysfunction. Nat Rev Neurosci 2015; 16: 55-61.
131. Palaniyappan L, Simmonite M, White TP et al. Neural primacy of the salience processing system in schizophrenia. Neuron 2013; 79: 814-28.
132. Menon V, Uddin LQ. Saliency, switching, attention and control: a network model of insula function. Brain Struct Funct 2010; 214: 655-67.
133. Roffman JL, Tanner AS, Eryilmaz H et al. Dopamine D1 signaling organizes network dynamics underlying working memory. Sci Adv 2016; 2:e1501672.
134. Braun U, Harneit A, Pergola G et al. Brain state stability during working memory is explained by network control theory, modulated by dopamine D1/D2 receptor function, and diminished in schizophrenia. bioRxiv 2019: 679670.
135. McCutcheon R, Nour MM, Dahoun T et al. Mesolimbic dopamine function is related to salience network connectivity: an integrative positron emission tomography and magnetic resonance study. Biol Psychiatry 2019; 85: 368-78.
136. Maia TV, Frank MJ. From reinforcement learning models to psychiatric and neurological disorders. Nat Neurosci 2011; 14: 154-62.
137. Krystal JH, Anticevic A, Yang GJ et al. Impaired tuning of neural ensembles and the pathophysiology of schizophrenia: a translational and computational neuroscience perspective. Biol Psychiatry 2017; 81: 874-85.
138. Schultz W. Predictive reward signal of dopamine neurons. J Neurophysiol 1998; 80: 1-27.
139. Maia TV, Frank MJ. An integrative perspective on the role of dopamine in schizophrenia. Biol Psychiatry 2017; 81: 52-66.
140. Strauss GP, Frank MJ, Waltz JA et al. Deficits in positive reinforcement learning and uncertainty-driven exploration are associated with distinct aspects of negative symptoms in schizophrenia. Biol Psychiatry 2011; 69: 424-31.
141. Gold JM, Waltz JA, Matveeva TM et al. Negative symptoms in schizophrenia result from a failure to represent the expected value of rewards: behavioral and computational modeling evidence. Arch Gen Psychiatry 2012; 69: 129-38.
142. Krystal JH, D'Souza DC, Gallinat J et al. The vulnerability to alcohol and substance abuse in individuals diagnosed with schizophrenia. Neurotox Res 2006; 10: 235-52.
143. MacCabe JH, Wicks S, Löfving S et al. Decline in cognitive performance between ages 13 and 18 years and the risk for psychosis in adulthood: a Swedish longitudinal cohort study in males. JAMA Psychiatry 2013; 70: 261-70.
144. Keefe RSE, Fenton WS. How should DSM-V criteria for schizophrenia include cognitive impairment? Schizophr Bull 2007; 33: 912-20.
145. Green MF, Horan PW, Lee J. Nonsocial and social cognition in schizophrenia: current evidence and future directions. World Psychiatry 2019; 18: 146-61.
146. Kelly S, Guimond S, Lyall A et al. Neural correlates of cognitive deficits across developmental phases of schizophrenia. Neurobiol Dis 2019; 131: 104353.
147. Arnsten AFT. Catecholamine modulation of prefrontal cortical cognitive function. Trends Cogn Sci 1998; 2: 436-47.
148. Schobel SA, Chaudhury NH, Khan UA et al. Imaging patients with psychosis and a mouse model establishes a spreading pattern of hippocampal dysfunction and implicates glutamate as a driver. Neuron 2013; 78: 81-93.
149. Lieberman JA, Girgis RR, Brucato G et al. Hippocampal dysfunction in the pathophysiology of schizophrenia: a selective review and hypothesis for early detection and intervention. Mol Psychiatry 2018; 23: 1764-72.
150. Moghaddam B, Javitt D. From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacology 2012; 37: 4-15.
151. Malhotra AK, Pinals DA, Adler CM et al. Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology 1997; 17: 141-50.
152. Al-Diwani A, Handel A, Townsend L et al. The psychopathology of NMDAR-antibody encephalitis in adults: a systematic review and phenotypic analysis of individual patient data. Lancet Psychiatry 2019; 6: 235-46.
153. Krystal JH, Karper LP, Seibyl JP et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994; 51: 199-214.
154. Carhart-Harris RL, Brugger S, Nutt DJ et al. Psychiatry's next top model: cause for a re-think on drug models of psychosis and other psychiatric disorders. J Psychopharmacol 2013; 27: 771-8.
155. Cheng WJ, Chen CH, Chen CK et al. Similar psychotic and cognitive profile between ketamine dependence with persistent psychosis and schizophrenia. Schizophr Res 2018; 199: 313-8.
156. Poels EMP, Kegeles LS, Kantrowitz JT et al. Imaging glutamate in schizophrenia: review of findings and implications for drug discovery. Mol Psychiatry 2014; 19: 20-9.
157. Bak LK, Schousboe A, Waagepetersen HS. The glutamate/GABA-glutamine cycle: aspects of transport, neurotransmitter homeostasis and ammonia transfer. J Neurochem 2006; 98: 641-53.
158. McKenna MC. The glutamate-glutamine cycle is not stoichiometric: fates of glutamate in brain. J Neurosci Res 2007; 85: 3347-58.
159. Merritt K, Egerton A, Kempton MJ et al. Nature of glutamate alterations in schizophrenia. JAMA Psychiatry 2016; 52: 998-1007.
160. Reid MA, Salibi N, White DM et al. 7T proton magnetic resonance spectroscopy of the anterior cingulate cortex in first-episode schizophrenia. Schizophr Bull 2019; 45: 180-9.
161. Wang AM, Pradhan S, Coughlin JM et al. Assessing brain metabolism with 7-T proton magnetic resonance spectroscopy in patients with first-episode psychosis. JAMA Psychiatry 2019; 76: 314-23.
162. Kumar J, Liddle EB, Fernandes CC et al. Glutathione and glutamate in schizophrenia: a 7T MRS study. Mol Psychiatry (in press).
163. Marsman A, Mandl RCW, Klomp DWJ et al. GABA and glutamate in schizophrenia: a 7T 1H-MRS study. Neuroimage Clin 2014; 6: 398-407.
164. Posporelis S, Coughlin JM, Marsman A et al. Decoupling of brain temperature and glutamate in recent onset of schizophrenia: a 7T proton magnetic resonance spectroscopy study. Biol Psychiatry Cogn Neurosci Neuroimaging 2018; 3: 248-54.
165. Brandt AS, Unschuld PG, Pradhan S et al. Age-related changes in anterior cingulate cortex glutamate in schizophrenia: a 1H MRS study at 7 Tesla. Schizophr Res 2016; 172: 101-5.
166. Taylor R, Neufeld RWJ, Schaefer B et al. Functional magnetic resonance spectroscopy of glutamate in schizophrenia and major depressive disorder: anterior cingulate activity during a color-word Stroop task. NPJ Schizophr 2015; 1: 15028.
167. Jelen LA, King S, Mullins PG et al. Beyond static measures: a review of functional magnetic resonance spectroscopy and its potential to investigate dynamic glutamatergic abnormalities in schizophrenia. J Psychopharmacol 2018; 32: 497-508.
168. Chiappelli J, Shi Q, Wijtenburg SA et al. Glutamatergic response to heat pain stress in schizophrenia. Schizophr Bull 2018; 44: 886-95.
169. Akkus F, Treyer V, Ametamey SM et al. Metabotropic glutamate receptor 5 neuroimaging in schizophrenia. Schizophr Res 2017; 183: 95-101.
170. Fu H, Chen Z, Josephson L et al. Positron emission tomography (PET) ligand development for ionotropic glutamate receptors: challenges and opportunities for radiotracer targeting N-methyl-d-aspartate (NMDA), α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), and kainate receptors. J Med Chem 2019; 62: 403-19.
171. Mason G, Petersen K, de Graaf RA et al. Measurements of the anaplerotic rate in the human cerebral cortex using 13C magnetic resonance spectroscopy and [1-13 C] and [2-13C] glucose. J Neurochem 2007; 100: 73-86.
172. Abdallah CG, De Feyter HM, Averill LA et al. The effects of ketamine on prefrontal glutamate neurotransmission in healthy and depressed subjects. Neuropsychopharmacology 2018; 43: 2154-60.
173. Sibson NR, Dhankhar A, Mason GF et al. Stoichiometric coupling of brain glucose metabolism and glutamatergic neuronal activity. Proc Natl Acad Sci USA 1998; 95: 316-21.
174. Cai K, Haris M, Singh A et al. Magnetic resonance imaging of glutamate. Nat Med 2012; 18: 302-6.
175. Roalf DR, Nanga RPR, Rupert PE et al. Glutamate imaging (GluCEST) reveals lower brain GluCEST contrast in patients on the psychosis spectrum. Mol Psychiatry 2017; 22: 1298-305.
176. Modinos G, S¸ ims¸ek F, Azis M et al. Prefrontal GABA levels, hippocampal resting perfusion and the risk of psychosis. Neuropsychopharmacology 2018; 43: 262-59. Web of Science
177. Liemburg E, Sibeijn-Kuiper A, Bais L et al. Prefrontal NAA and Glx levels in different stages of psychotic disorders: a 3T 1H-MRS study. Sci Rep 2016; 6: 1-8.
178. Da Silva T, Hafizi S, Rusjan PM et al. GABA levels and TSPO expression in people at clinical high risk for psychosis and healthy volunteers: a PET-MRS study. J Psychiatry Neurosci 2019; 44: 111-9.
179. Hädel S, Wirth C, Rapp M et al. Effects of age and sex on the concentrations of glutamate and glutamine in the human brain. J Magn Reson Imaging 2013; 38: 1480-7.
180. Tayoshi S, Sumitani S, Taniguchi K et al. Metabolite changes and gender differences in schizophrenia using 3-Tesla proton magnetic resonance spectroscopy (1H-MRS). Schizophr Res 2009; 108: 69-77.
181. Grachev I, Apkarian A. Aging alters regional multichemical profile of the human brain: an in vivo 1H-MRS study of young versus middle-aged subjects. J Neurochem 2001; 76: 582-93.
182. Merritt K, McGuire P, Egerton A. Relationship between glutamate dysfunction and symptoms and cognitive function in psychosis. Front Psychiatry 2013; 4: 151.
183. Lutkenhoff ES, van Erp TG, Thomas MA et al. Proton MRS in twin pairs discordant for schizophrenia. Mol Psychiatry 2010; 15: 308-18.
184. Tebartz Van Elst L, Valerius G, Büchert M et al. Increased prefrontal and hippocampal glutamate concentration in schizophrenia: evidence from a magnetic resonance spectroscopy study. Biol Psychiatry 2005; 58: 724-30.
185. Wang M, Yang Y, Wang CJ et al. NMDA receptors subserve persistent neuronal firing during working memory in dorsolateral prefrontal cortex. Neuron 2013; 77: 736-49.
186. Harris KD, Mrsic-Flogel TD. Cortical connectivity and sensory coding. Nature 2013; 503: 51-8.
187. Buzsáki G, Watson BO. Brain rhythms and neural syntax: implications for efficient coding of cognitive content and neuropsychiatric disease. Dialogues Clin Neurosci 2012; 14: 345-67.
188. Lin AC, Bygrave AM, De Calignon A et al. Sparse, decorrelated odor coding in the mushroom body enhances learned odor discrimination. Nat Neurosci 2014; 17: 559-68.
189. Murray JD, Anticevic A, Gancsos M et al. Linking microcircuit dysfunction to cognitive impairment: effects of disinhibition associated with schizophrenia in a cortical working memory model. Cereb Cortex 2014; 24: 859-72.
190. Uhlhaas PJ, Singer W. Abnormal neural oscillations and synchrony in schizophrenia. Nat Rev Neurosci 2010; 11: 100-13.
191. Lewis DA, Curley AA, Glausier JR et al. Cortical parvalbumin interneurons and cognitive dysfunction in schizophrenia. Trends Neurosci 2012; 35: 57-67.
192. Coyle J. Glutamate and schizophrenia: beyond the dopamine hypothesis. Cell Mol Neurobiol 2006; 26: 365-84.
193. Pers TH, Timshel P, Ripke S et al. Comprehensive analysis of schizophrenia-associated loci highlights ion channel pathways and biologically plausible candidate causal genes. Hum Mol Genet 2015; 25: 1247-54. Web of Science
194. Ma C, Gu C, Huo Y et al. The integrated landscape of causal genes and pathways in schizophrenia. Transl Psychiatry 2018; 8: 67.
195. Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological insights from 108 schizophrenia-associated genetic loci. Nature 2014; 511: 421-7.
196. Edwards AC, Bacanu S, Bigdeli TB et al. Evaluating the dopamine hypothesis of schizophrenia in a large-scale genome-wide association study. Schizophr Res 2016; 176: 136-40.
197. D'Ambrosio E, Dahoun T, Pardiñas AF et al. The effect of a genetic variant at the schizophrenia associated AS3MT/BORCS7 locus on striatal dopamine function: a PET imaging study. Psychiatry Res Neuroimaging 2019; 291: 34-41.
198. Dahoun T, Pardiñas AF, Veronese M et al. The effect of the DISC1 Ser704Cys polymorphism on striatal dopamine synthesis capacity: an [18F]-DOPA PET study. Hum Mol Genet 2018; 27: 3498-506.
199. Pocklington AJ, Rees E, Walters JTR et al. Novel findings from CNVs implicate inhibitory and excitatory signaling complexes in schizophrenia. Neuron 2015; 86: 1203-14.
200. Timms AE, Dorschner MO, Wechsler J et al. Support for the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia from exome sequencing in multiplex families. JAMA Psychiatry 2013; 70: 582-90.
201. Brennand K, Savas JN, Kim Y et al. Phenotypic differences in hiPSC NPCs derived from patients with schizophrenia. Mol Psychiatry 2015; 20: 361-8.
202. Robicsek O, Karry R, Petit I et al. Abnormal neuronal differentiation and mitochondrial dysfunction in hair follicle-derived induced pluripotent stem cells of schizophrenia patients. Mol Psychiatry 2013; 18: 1067-76.
203. Hook V, Brennand KJ, Kim Y et al. Human iPSC neurons display activity-dependent neurotransmitter secretion: aberrant catecholamine levels in schizophrenia neurons. Stem Cell Reports 2014; 3: 531-8.
204. Hartley BJ, Tran N, Ladran I et al. Dopaminergic differentiation of schizophrenia hiPSCs. Mol Psychiatry 2015; 20: 549-50.
205. Brennand KJ, Simone A, Jou J et al. Modelling schizophrenia using human induced pluripotent stem cells. Nature 2011; 473: 221-5.
206. Wen Z, Nguyen HN, Guo Z et al. Synaptic dysregulation in a human iPS cell model of mental disorders. Nature 2014; 515: 414-8.
207. Yu DX, Di Giorgio FP, Yao J et al. Modeling hippocampal neurogenesis using human pluripotent stem cells. Stem Cell Reports 2014; 2: 295-310.
208. Pruessner JC, Champagne F, Meaney MJ et al. Dopamine release in response to a psychological stress in humans and its relationship to early life maternal care: a positron emission tomography study using [11C]raclopride. J Neurosci 2004; 24: 2825-31.
209. Vaessen T, Hernaus D, Myin-Germeys I et al. The dopaminergic response to acute stress in health and psychopathology: a systematic review. Neurosci Biobehav Rev 2015; 56: 241-51.
210. Egerton A, Howes OD, Houle S et al. Elevated striatal dopamine function in immigrants and their children: a risk mechanism for psychosis. Schizophr Bull 2017; 43: 293-301. Web of Science
211. Egerton A, Valmaggia LR, Howes OD et al. Adversity in childhood linked to elevated striatal dopamine function in adulthood. Schizophr Res 2016; 176: 171-6.
212. Radua J, Ramella-Cravaro V, Ioannidis JPA et al. What causes psychosis? An umbrella review of risk and protective factors. World Psychiatry 2018; 17: 49-66.
213. Morgan C, Knowles G, Hutchinson G. Migration, ethnicity and psychoses: evidence, models and future directions. World Psychiatry 2019; 18: 247-58.
214. Bloomfield MA, Morgan CJ, Egerton A et al. Dopaminergic function in cannabis users and its relationship to cannabis-induced psychotic symptoms. Biol Psychiatry 2014; 75: 470-8.
215. Mizrahi R, Suridjan I, Kenk M et al. Dopamine response to psychosocial stress in chronic cannabis users: a PET study with [11C]-+-PHNO. Neuropsychopharmacology 2013; 38: 673-82.
216. Popoli M, Yan Z, McEwen BS et al. The stressed synapse: the impact of stress and glucocorticoids on glutamate transmission. Nat Rev Neurosci 2012; 13: 22-37. CASWeb of Science
217. Houtepen LC, Schür RR, Wijnen JP et al. Acute stress effects on GABA and glutamate levels in the prefrontal cortex: a 7T 1H-magnetic resonance spectroscopy study. Neuroimage Clin 2017; 14: 195-200.
218. Colizzi M, McGuire P, Pertwee RG et al. Effect of cannabis on glutamate signalling in the brain: a systematic review of human and animal evidence. Neurosci Biobehav Rev 2016; 64: 359-81.
219. Guennewig B, Bitar M, Obiorah I et al. THC exposure of human iPSC neurons impacts genes associated with neuropsychiatric disorders. Transl Psychiatry 2018; 8: 89.
220. White TL, Monnig MA, Walsh EG et al. Psychostimulant drug effects on glutamate, Glx, and creatine in the anterior cingulate cortex and subjective response in healthy humans. Neuropsychopharmacology 2018; 43: 1498-509.
221. Egerton A, Bhachu A, Merritt K et al. Effects of antipsychotic administration on brain glutamate in schizophrenia: a systematic review of longitudinal (1)H-MRS studies. Front Psychiatry 2017; 8: 66.
222. Kokkinou M, Ashok A, Howes O. The effects of ketamine on dopaminergic function: meta-analysis and review of the implications for neuropsychiatric disorders. Mol Psychiatry 2018; 23: 59-69.
223. Krystal JH, D'Souza DC, Karper LP et al. Interactive effects of subanesthetic ketamine and haloperidol in healthy humans. Psychopharmacology 1999; 145: 193-204.
224. Gleich T, Deserno L, Lorenz RC et al. Prefrontal and striatal glutamate differently relate to striatal dopamine: potential regulatory mechanisms of striatal presynaptic dopamine function? J Neurosci 2015; 35: 9615-21.
225. Jauhar S, McCutcheon R, Borgan F et al. The relationship between cortical glutamate and striatal dopamine in first-episode psychosis: a cross-sectional multimodal PET and magnetic resonance spectroscopy imaging study. Lancet Psychiatry 2018; 5: 816-23.
226. Stone JM, Howes OD, Egerton A et al. Altered relationship between hippocampal glutamate levels and striatal dopamine function in subjects at ultra high risk of psychosis. Biol Psychiatry 2010; 68: 599-602.
227. Schwartz TL, Sachdeva S, Stahl SM. Glutamate neurocircuitry: theoretical underpinnings in schizophrenia. Front Pharmacol 2012; 3: 195.
228. Chun S, Westmoreland JJ, Bayazitov IT et al. Specific disruption of thalamic inputs to the auditory cortex in schizophrenia models. Science 2014; 344: 1178-82.
229. Gao WJ, Krimer LS, Goldman-Rakic PS. Presynaptic regulation of recurrent excitation by D1 receptors in prefrontal circuits. Proc Natl Acad Sci USA 2001; 98: 295-300.
230. Howes OD, McCutcheon R, Agid O et al. Treatment-resistant schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group consensus guidelines on diagnosis and terminology. Am J Psychiatry 2017; 174: 216-29.
231. Jauhar S, Veronese M, Nour MM et al. Determinants of treatment response in first-episode psychosis: an 18F-DOPA PET study. Mol Psychiatry 2019; 24: 1502-12.
232. Tamminga CA, Schaffer MH, Smith RC et al. Schizophrenic symptoms improve with apomorphine. Science 1978; 200: 567-8.
233. Jauhar S, Veronese M, Rogdaki M et al. Regulation of dopaminergic function: an [18F]-DOPA PET apomorphine challenge study in humans. Transl Psychiatry 2017; 7:e1027.
234. Revel FG, Moreau J-L, Gainetdinov RR et al. TAAR1 activation modulates monoaminergic neurotransmission, preventing hyperdopaminergic and hypoglutamatergic activity. Proc Natl Acad Sci USA 2011; 108: 8485-90.
235. Foster DJ, Wilson JM, Remke DH et al. Antipsychotic-like effects of M4 positive allosteric modulators are mediated by CB2 receptor-dependent inhibition of dopamine release. Neuron 2016; 91: 1244-52.
236. Shekhar A, Potter WZ, Lightfoot J et al. Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. Am J Psychiatry 2008; 165: 1033-9.
237. Heckman PRA, Blokland A, Bollen EPP et al. Phosphodiesterase inhibition and modulation of corticostriatal and hippocampal circuits: clinical overview and translational considerations. Neurosci Biobehav Rev 2018; 87: 233-54.
238. Kuroiwa M, Snyder GL, Shuto T et al. Phosphodiesterase 4 inhibition enhances the dopamine D1 receptor/PKA/DARPP-32 signaling cascade in frontal cortex. Psychopharmacology 2012; 219: 1065-79.
239. Cohen SM, Tsien RW, Goff DC et al. The impact of NMDA receptor hypofunction on GABAergic neurons in the pathophysiology of schizophrenia. Schizophr Res 2015; 167: 98-107.
240. Alherz F, Alherz M, Almusawi H. NMDAR hypofunction and somatostatin-expressing GABAergic interneurons and receptors: a newly identified correlation and its effects in schizophrenia. Schizophr Res Cogn 2017; 8: 1-6.
241. Singh SP, Singh V. Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia. CNS Drugs 2011; 25: 859-85.
242. Weiser M, Heresco-Levy U, Davidson M et al. A multicenter, add-on randomized controlled trial of low-dose d-serine for negative and cognitive symptoms of schizophrenia. J Clin Psychiatry 2012; 73: e728-34. CAS
243. Iwata Y, Nakajima S, Suzuki T et al. Effects of glutamate positive modulators on cognitive deficits in schizophrenia: a systematic review and meta-analysis of double-blind randomized controlled trials. Mol Psychiatry 2015; 20: 1151-60.
244. Beck K, Javitt DC, Howes OD. Targeting glutamate to treat schizophrenia: lessons from recent clinical studies. Psychopharmacology 2016; 233: 2425-28.
245. Goff D. Bitopertin: the good news and bad news. JAMA Psychiatry 2014; 71: 621-2.
246. D'Souza DC, Carson RE, Driesen N et al. Dose-related target occupancy and effects on circuitry, behavior, and neuroplasticity of the glycine transporter-1 inhibitor PF-03463275 in healthy and schizophrenia subjects. Biol Psychiatry 2018; 84: 413-21.
247. Balu DT, Coyle JT. The NMDA receptor “glycine modulatory site” in schizophrenia: D-serine, glycine, and beyond. Curr Opin Pharmacol 2015; 20: 109-15.
248. Zheng W, Cai DB, Yang XH et al. Adjunctive celecoxib for schizophrenia: a meta-analysis of randomized, double-blind, placebo-controlled trials. J Psychiatr Res 2017; 92: 139-46.
249. Zakrocka I, Targowska-Duda KM, Wnorowski A et al. Influence of cyclooxygenase-2 inhibitors on kynurenic acid production in rat brain in vitro. Neurotox Res 2019; 35: 244-54.
250. Anticevic A, Cole MW, Repovs G et al. Connectivity, pharmacology, and computation: toward a mechanistic understanding of neural system dysfunction in schizophrenia. Front Psychiatry 2013; 4: 169.
251. Ellaithy A, Younkin J, González-Maeso J et al. Positive allosteric modulators of metabotropic glutamate 2 receptors in schizophrenia treatment. Trends Neurosci 2015; 38: 506-16.
252. Krystal JH, Abi-Saab W, Perry E et al. Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects. Psychopharmacology 2005; 179: 303-9.
253. Uno Y, Coyle JT. Glutamate hypothesis in schizophrenia. Psychiatry Clin Neurosci 2019; 73: 204-15.
254. Pillinger T, Rogdaki M, Mccutcheon RA et al. Altered glutamatergic response and functional connectivity in treatment resistant schizophrenia: the effect of riluzole and therapeutic implications. Psychopharmacology 2019; 236: 1985-97.
255. Farokhnia M, Sabzabadi M, Pourmahmoud H et al. A double-blind, placebo controlled, randomized trial of riluzole as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia. Psychopharmacology 2014; 231: 533-42.
256. Anand A, Charney DS, Oren DA et al. Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists. Arch Gen Psychiatry 2000; 57: 270-6.
257. Tiihonen J, Wahlbeck K, Kiviniemi V. The efficacy of lamotrigine in clozapine-resistant schizophrenia: a systematic review and meta-analysis. Schizophr Res 2009; 109: 10-4.
258. Mouchlianitis E, McCutcheon R, Howes OD. Brain-imaging studies of treatment-resistant schizophrenia: a systematic review. Lancet Psychiatry 2016; 3: 451-63.
259. Egerton A, Broberg BV, Van Haren N et al. Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre 1H-MRS study (OPTiMiSE). Mol Psychiatry 2018; 23: 2145-55.
260. Demjaha A, Egerton A, Murray RM et al. Antipsychotic treatment resistance in schizophrenia associated with elevated glutamate levels but normal dopamine function. Biol Psychiatry 2014; 75: e11-3.
261. Mouchlianitis E, Bloomfield MAP, Law V et al. Treatment-resistant schizophrenia patients show elevated anterior cingulate cortex glutamate compared to treatment-responsive. Schizophr Bull 2016; 42: 744-52.
262. Kennedy JA, Israel O, Frenkel A et al. Super-resolution in PET imaging. IEEE Trans Med Imaging 2006; 25: 137-47.
263. Song T-A, Chowdhury SR, Yang F et al. Super-resolution PET imaging using convolutional neural networks. Submitted for publication.
264. McCutcheon R, Pillinger T, Mizuno Y et al. The efficacy and heterogeneity of antipsychotic response in schizophrenia: a meta-analysis. Mol Psychiatry (in press).
265. Javitt DC, Carter CS, Krystal JH et al. Utility of imaging-based biomarkers for glutamate-targeted drug development in psychotic disorders. JAMA Psychiatry 2018; 75: 11-9.
266. van den Heuvel MP, Scholtens LH, Kahn RS. Multiscale neuroscience of psychiatric disorders. Biol Psychiatry 2019; 86: 512-22.
267. Breakspear M. Dynamic models of large-scale brain activity. Nat Neurosci 2017; 20: 340-52.

ЖУРНАЛЫ

ИНТЕРАКТИВ

СПЕЦИАЛИЗАЦИИ

ИЗДАНИЯ-ПАРТНЕРЫ

Дофамин и глутамат при шизофрении

Материал для специалистов

ЖУРНАЛЫ

ИНТЕРАКТИВ

СПЕЦИАЛИЗАЦИИ

ИЗДАНИЯ-ПАРТНЕРЫ

Дофамин и глутамат при шизофрении

Материал для специалистов

Con-Med Passport